2018 Cosbie Lecture Canadian Cancer Trials Group Annual Spring Meeting of Participants 28 April 2018 Toronto, Ontario Sponsored By: Canadian Oncology Societies / Cancer Care Ontario / Canadian Cancer Trials Group CRAIG EARLE, MD, MSc, FRCPC How Can We Introduce Innovative Treatments into our Publicly-Funded Healthcare System? Dr. Craig Earle is a medical oncologist at Sunnybrook Health Sciences Centre Odette Cancer Centre in Toronto, Ontario. He is Vice-President of Cancer Control at the Canadian Partnership Against Cancer, a Senior Scientist at the Institute for Clinical Evaluative Sciences, and a Professor of Medicine at the University of Toronto. He is past Chair of the Ontario Steering Committee for Cancer Drug Programs and is a current member of the pan-Canadian Oncology Drug Review Expert Review Committee. His personal research focuses on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effects of financial incentives on care delivery, and making linked, de-identified administrative data more available for health research. Dr. Earle originally trained and practiced in Ottawa, after which, beginning in 1998, he spent 10 years in Boston at Harvard Medical School and the Harvard School of Public Health. Between 2008-2017, he was Director of Health Services Research and Head of Clinical Translation at the Ontario Institute for Cancer Research. In 1976, the Ontario Cancer Treatment and Research Foundation established a lectureship in honour of Dr. W. Gerald Cosbie Biography Dr. Cosbie was born in Toronto on January 29, 1894. He was educated at Upper Canada College as well as the University of Toronto Medical School. After graduating in 1915, he joined the Royal Canadian Army Medical Corps. He served with the Third Canadian Division and was wounded at Vimy Ridge. His distinguished service saw him awarded the Military Cross for outstanding bravery. Upon his return to Canada in 1919, he undertook graduate studies and became a Fellow of the Royal College of Surgeons of Canada, as well as a Fellow of the Royal College of Obstetricians and Gynaecologists. He pioneered and refined certain treatments for gynaecological cancer. On September 13, 1921, he cared for the first patients who were treated with radiotherapy at the Toronto General Hospital (TGH). Dr. Cosbie was a gynaecological consultant at the Ontario Institute of Radiotherapy at the TGH when his colleague, Dr. Gordon Richards, died in 1949. Despite the demands of a busy practice and lecturing and clinical commitments at the University of Toronto and at the TGH, Dr. Cosbie stepped in to fill the void left by Dr. Richards. Dr. Cosbie succeeded him as a member of the Ontario Cancer Treatment and Research Foundation, as Chairman of the Advisory Medical Board and its Executive Committee. He also played an important role in discussions with the provincial government, ultimately leading to the establishment of the Ontario Cancer Institute. He retired from the staff of the university in 1954 and accepted the post of Medical Director of the Foundation, on a part-time basis. Dr. Cosbie had unofficially been performing these duties since 1949. The position became full-time once he retired from his private practice. In 1957 Dr. Cosbie became Vice-chairman of the Foundation, a post he held until 1971. On June 30, 1965, Dr. Cosbie stepped down from his post as Medical Director. Under his vigorous and able leadership, many new programs had been introduced and existing programs improved and expanded. He was an entertaining raconteur, a fluent speaker, and a skilled writer, making him an excellent representative of the Foundation and a strong proponent of its work. In 1973, after moving to Vancouver, Dr. Cosbie resigned from the Board after serving the Foundation and the Advisory Medical Board committees for many years. The first Cosbie Lecture, which was awarded to the newly-formed Canadian Oncology Society, was delivered on January 27, 1977 in Toronto, by Mr. Basil Morson, the distinguished pathologist of St. Mark’s Hospital in London, England. Dr. Cosbie was on hand for the occasion. Past Lectures Year Lecturer 2017 Dr. Gerald Batist Toronto, ON Precision Medicine Requires Precise Targets and a Community of Patients 2016 Dr. Mary Gospodarowicz Toronto, ON Global Cancer Control - Challenges and Opportunities 2015 Dr. Joseph M. Connors Vancouver, BC Yin and Yang: Population-Based Studies and Clinical Trials – Lessons from Lymphoid Cancer 2014 Dr. Ian Tannock Toronto, ON Whither (or Wither?) the Randomised Clinical Trial? 2013 Dr. Elizabeth Eisenhauer Kingston, ON Initiatives to Advance the State of Cancer Clinical Trials in Canada – Hope in Spring 2012 Dr. Robert Califf Durham, NC The American Clinical Trials Enterprise: Are We Reaching the Tipping Point for Transformation? 2011 Dr. Bernard Cummings Toronto, ON Radiation Therapy, Rectal Cancer and Clinical Trials: Lessons and Opportunities 2010 Dr. Hartley S. Stern Montreal, QC 5 Year Survival of Clinical Cancer Trials in Canada: Perspective of a Lapsed Investigator 2009 Dr. Frances A. Shepherd Toronto, ON Lung Cancer: A Journey from Nihilism to Hope Through Bench to Bedside Research 2008 Dr. Kathleen Pritchard Toronto, ON Thirty Years of Breast Cancer Research in the NCIC CTG" or " How time flies when you're having fun" 2007 Dr. Joseph Pater Kingston, ON Clinical Research in Canada: Four Decades in Evolution 2006 Dr. George Browman Toronto, ON Five Steps: Introducing a Tool to Facilitate Resource Allocation Decisions About Cancer Care Drug Funding 2004 Dr. Anthony Fields Edmonton, AB Evolution of Cancer Advocacy in Canada 2002 Dr. Steven Gallinger Toronto, ON Impact of Genetics and Clinical Care of Patients and their Families Archive 2001 - 1977 Year Lecturer 2001 Dr. Charles Weijer - Halifax, NS 2000 Dr. John Potter - Seattle, WA 1999 Dr. Richard Bakemeier - Denver, CO 1998 Dr. David Osoba - Vancouver, BC 1997 Dr. Janet Rowley - Chicago, IL 1998 Dr. David Osoba - Vancouver, BC 1997 Dr. Janet Rowley - Chicago, IL 1996 Dr. Balfour Mount - Montreal, QC 1995 Dr. Henry Shibata - Montreal, QC 1994 Dr. Joseph Pater - Kingston, ON 1993 Dr. Jack Roth 1992 Dr. W. Thomas - Seattle, WA 1991 Dr. Alan Gerulath 1990 Dr. James H. Goldie - British Columbia 1989 Dr. James Cox - Houston, TX 1988 Dr. Charles Balch - Houston, TX 1987 Dr. David Schottenfeld - Ann Arbor, MI 1986 Dr. D.E. Bergsagel - Toronto, ON 1985 Dr. David Boyes - British Columbia 1984 Dr. Robert W. Bruce - Toronto, ON 1983 Dr. Oliver Beahrs - Rochester, MN 1982 Dr. R.B. Livingston 1981 Dr. Malcolm A. Bagshaw - California 1980 Dr. J.P. Smith - Detroit, MI 1979 Dr. E.L. Wynder - New York, NY 1978 Dr. Marvin Schneiderman - Washington, DC 1977 Mr. Basil Morson - London, England
Dr. Craig Earle is a medical oncologist at Sunnybrook Health Sciences Centre Odette Cancer Centre in Toronto, Ontario. He is Vice-President of Cancer Control at the Canadian Partnership Against Cancer, a Senior Scientist at the Institute for Clinical Evaluative Sciences, and a Professor of Medicine at the University of Toronto. He is past Chair of the Ontario Steering Committee for Cancer Drug Programs and is a current member of the pan-Canadian Oncology Drug Review Expert Review Committee. His personal research focuses on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effects of financial incentives on care delivery, and making linked, de-identified administrative data more available for health research. Dr. Earle originally trained and practiced in Ottawa, after which, beginning in 1998, he spent 10 years in Boston at Harvard Medical School and the Harvard School of Public Health. Between 2008-2017, he was Director of Health Services Research and Head of Clinical Translation at the Ontario Institute for Cancer Research.